NGNE · Neurogene Inc.
$26.47
+0.82 (+3.20%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$566.52M
Shares
20.01M
Volume · Oct 5
211.77K
Avg daily vol (3M)
261.24K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$26.47
Open$25.71
Day$24.87–26.76
52W close$16.37–42.84
Avg vol 30d300K
Short int3.3M · 16.4% float · 16.9d
Short vol79%
Last earningsAug 11, 2025
DataJan 2020–Oct 2026
Filing10-Q · Aug 11
Up next
filed Aug 11, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$111.11M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-15.5%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$225.39M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+7.1%
Year over year · more shares
Price change (1Y)
+22.3%
Trailing year
Short interest
16.4%
Latest settlement · 16.9 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Strong
Sentiment
Neutral
Fundamentals
Poor
Quant / Vol
Very High
Market backdrop
VIX 15.5 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−3%
below
Price vs 50-day avg
−23%
below
RSI (14)
29
oversold
MACD trend
Negative
52-week position
38%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−31%
trailing
6-month return
+28%
trailing
YTD return
+29%
this year
Relative strength
+16%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $35 › 200d $27 — 50d above 200d
Institutional flow
Accumulating
1 of 112 funds reported for Sep 30 · net +50 sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
16.39% of float · ▲ +4.6% MoM · 16.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
112 holders — near 6-yr high, broad support
Squeeze score
75
high risk · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
+1%
Y/Y
Free cash flow
$-78.4M
Quant / Vol
risk profile
Volatility
81%
annualized · 1-yr
Max drawdown
−52%
past year
ATR
7.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−3%
Neutral
Price vs 50-day avg
−23%
Bearish
RSI (14)
29
Neutral
MACD trend
Negative
Bearish
52-week position
38%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $35 › 200d $27 — 50d above 200d
Institutional flow
Accumulating
1 of 112 funds reported for Sep 30 · net +50 sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
16.39% of float · ▲ +4.6% MoM · 16.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
112 holders — near 6-yr high, broad support
Price context
position in its 52-week range
Range low $16
Now $26 · 38%
Range high $43
vs 200-day avg -3%
vs 50-day avg -23%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NGNE
this stock
Neurogene Inc.
|
$566.52M | +28.5% | -100.0% | — | 16.4% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.1% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -5.9% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +589.1% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NGNE | -7.1% | -31.4% | +27.5% | -4.9% | +28.5% |
| SPY | +1.2% | +0.6% | +11.6% | +1.6% | +13.6% |
| vs SPY | -8.3% | -32.0% | +15.9% | -6.5% | +14.9% |